Results 141 to 150 of about 411,617 (199)

Safety and glycemic control with insulin degludec use in clinical practice: results from a 3-year Japanese post-marketing surveillance study. [PDF]

Diabetol Int
Murata T, Husemoen LLN, Nemoto S, Matsuhisa M.   +3 more
europepmc   +1 more source

Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials

Diabetes and Metabolism, 2020
Insulin degludec is a new ultra-long-action basal insulin. Using treat-to-target protocols, controlled trials have shown comparable HbA reductions with insulin degludec and comparators in both type 1 and type 2 diabetes.
V Preumont, M Buysschaert
exaly   +2 more sources

Clinical use of insulin degludec

Diabetes Research and Clinical Practice, 2015
The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties ...
Ambrish Mithal, Bertrand Cariou, Stewart B Harris   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Degludec: A Novel Basal Insulin

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012
Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these
Sanjay, Kalra, Manash P, Baruah, Asfandyar K, Niazi   +2 more
openaire   +3 more sources

Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus

Drugs, 2013
Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-to-day variability in glucose ...
openaire   +3 more sources

▼Insulin degludec for diabetes mellitus

Drug and Therapeutics Bulletin, 2013
Over the last few years there has been a steady increase in the number of prescriptions dispensed in primary care for intermediate and long-acting insulin analogues and a reduction in prescriptions for biphasic isophane insulin. For example, in England, the volume of intermediate and long-acting insulin analogues in general practice has risen from ...
openaire   +2 more sources

Insulin Degludec: A Novel Basal Insulin Analogue

Annals of Pharmacotherapy, 2013
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and potential role in therapy of insulin degludec. DATA SOURCES: Articles were identified using the MEDLINE database (January 1996-December ...
Jennifer D, Goldman-Levine, Dhiren K, Patel, David M, Schnee   +2 more
openaire   +2 more sources